Hello, if we wanted to prepare a promotional email for the representatives to send to HCPs that included both efficacy and safety claims in one email, is that permitted?
H
HRJ2021
@HRJ2021
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
Posts
-
Efficacy and Safety Studies in One Email -
Sharing an unbranded patient resourceHello,
We would like PAAB’s guidance on the acceptability of a resource that a company would like to share at a conference booth. The conference is organized by a patient association, and this is a booth for patients on therapies in a certain therapeutic area. Our company is only including unbranded disease awareness information at the booth. The company originally developed a doctor discussion guide to give to patients on one of the company’s therapies in a particular therapeutic area (the company has multiple products in this therapeutic area). The document is unbranded with respect to product but includes the company name at the bottom of the document. The document is a ‘fill in the black’ document that is intended to be used for conversations with the patient’s prescribing HCP and it includes prompts to complete based on your experience (e.g., my current treatment experience is _______, here’s what is going well with my treatment _______, here is what could be improved about my treatment ________). Would this be acceptable to share with members of the patient association at a booth?